DRMAW vs. ATNFW, SXTPW, DRTSW, APLMW, ARTLW, BCDAW, BCTXW, CDIOW, CTCXW, and SAVAW
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), Artelo Biosciences (ARTLW), BioCardia (BCDAW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), and Cassava Sciences (SAVAW). These companies are all part of the "biotechnology" industry.
180 Life Sciences (NASDAQ:ATNFW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
In the previous week, Dermata Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for 180 Life Sciences. Dermata Therapeutics' average media sentiment score of 1.00 beat 180 Life Sciences' score of -0.01 indicating that 180 Life Sciences is being referred to more favorably in the media.
180 Life Sciences and Dermata Therapeutics both received 0 outperform votes by MarketBeat users.
Summary
180 Life Sciences and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DRMAW vs. The Competition
Dermata Therapeutics Competitors List
Related Companies and Tools
